title: Isolation and characterization of a human colon carcinoma-secreted enzyme with pancreatic ribonuclease-like activity.
abstract: A ribonuclease was isolated from serum-free supernatants of the human colon adenocarcinoma cell line HT-29. It was purified by cation-exchange and C18 reversed-phase high-performance liquid chromatography. The protein is basic, has a molecular weight of approximately 16,000, and has an amino acid composition that is significantly different from that of human pancreatic ribonuclease. The amino terminus is blocked, and the carboxyl-terminal residue is glycine. The catalytic properties of this ribonuclease resemble those of the pancreatic ribonucleases in numerous respects. Thus, it exhibits a pH optimum of approximately 6 for dinucleotide cleavage and employs a two-step mechanism in which transphosphorylation to a cyclic 2',3'-phosphate is followed by slower hydrolysis to produce a 3'-phosphate. It does not cleave NpN' substrates in which adenosine or guanosine is at the N position and prefers purines at the N' position. Like bovine ribonuclease A, the HT-29-derived ribonuclease is inactivated by reductive methylation or by treatment with iodoacetate at pH 5.5 and is strongly inhibited by the human placental ribonuclease inhibitor. However, in contrast, the tumor enzyme does not cleave CpN bonds at an appreciable rate and prefers poly(uridylic acid) as substrate 1000-fold over poly(cytidylic acid). It also hydrolyzes cytidine cyclic 2',3'-phosphate at least 100 times more slowly than uridine cyclic 2',3'-phosphate and is inhibited much less strongly by cytidine 2'-monophosphate than by uridine 2'-monophosphate. Other ribonucleases known to prefer poly(uridylic acid) were isolated both from human serum and from liver and were compared with the tumor enzyme. The physical, functional, and chromatographic properties of the serum ribonuclease are essentially identical with those of the tumor enzyme. The liver enzymes, however, differ markedly from the HT-29 ribonuclease. The potential utility of the tumor ribonuclease in the diagnosis of cancer is considered.
authors.forename: R
authors.initials: R
authors.lastname: Shapiro
authors.forename: J W
authors.initials: JW
authors.lastname: Fett
authors.forename: D J
authors.initials: DJ
authors.lastname: Strydom
authors.forename: B L
authors.initials: BL
authors.lastname: Vallee
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology* / Q000378:metabolism; D000596:Amino Acids / Q000032:analysis; D000818:Animals; D002417:Cattle; D002460:Cell Line; D003110:Colonic Neoplasms / Q000201:enzymology* / Q000378:metabolism; D015226:Dinucleoside Phosphates; D006801:Humans; D007700:Kinetics; D008970:Molecular Weight; D009841:Oligonucleotides / Q000378:metabolism; D010179:Pancreas / Q000201:enzymology; D012259:Ribonuclease, Pancreatic / Q000378:metabolism*; D012260:Ribonucleases / Q000302:isolation & purification / Q000378:metabolism*; D013379:Substrate Specificity
chemical_list: D000596:Amino Acids; D015226:Dinucleoside Phosphates; D009841:Oligonucleotides; D012260:Ribonucleases; D012259:Ribonuclease, Pancreatic